Company news

Monte Rosa Therapeutics, Inc. news in 2023

Monte Rosa Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 8, 2023

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

November 6, 2023

Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

October 25, 2023

Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases

October 16, 2023

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

October 16, 2023

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 9, 2023

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

July 25, 2023

Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases

May 22, 2023

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 10, 2023

Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

March 22, 2023

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 15, 2023

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

January 8, 2023

Decks in 2023